The sale netted about $300 million for Walgreens and shrinks the company’s stake in Cencora to approximately 6%, down from 10 ...

In yet another move to pay down debt that matures in 2026, Walgreens Boots Alliance announced last night it would receive ...

S&P Global Ratings has revised its outlook on McKesson Corp (NYSE:MCK). to positive from stable, while affirming its 'BBB+' ...

Walgreens has sold more shares of drug distributor Cencora for proceeds of about $300 million in the latest effort to pay ...

Cencora simplifies distribution logistics by shipping products to centralized wholesaler locations, as opposed to shipping directly to pharmacies and various customer locations. Additionally, Cencora ...

Cencora is now targeting an 8% to 10% rise in revenue for the full fiscal year, a lift from its previous guidance for 7% to 9% growth. Sales are expected to rise 9% to 11% in its U.S. healthcare ...

Drug distributor Cencora raised its fiscal 2025 profit forecast on Wednesday, driven by robust demand for expensive specialty medicines.

Morgan Stanley analyst Erin Wright maintained a Hold rating on Cencora (COR – Research Report) today and set a price target of $263.00. The company’s shares closed yesterday at $254.89.

Shares of Cencora (COR) have been strong performers lately, with the stock up 13.4% over the past month. The stock hit a new 52-week high of $256.81 in the previous session. Cencora has gained 13. ...

We recently published a list of Jim Cramer’s Latest Calls: 10 Stocks to Buy or Sell. In this article, we are going to take a look at where Cardinal Health, Inc. (NYSE:CAH) stands against other stocks ...